XML 64 R51.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]        
Goodwill acquired     $ 2,000,000.0  
IPR and D Drug Technology Platforms [Member] | In Process Research and Development [Member]        
Finite-Lived Intangible Assets [Line Items]        
Asset impairment charges       $ 0
EGEN Inc [Member] | Goodwill [Member]        
Finite-Lived Intangible Assets [Line Items]        
Asset impairment charges       2,000,000.0
Non-cash charge   $ 2,000,000.0    
EGEN Inc [Member] | Purchase Agreement [Member]        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible assets acquired     $ 1,600,000  
Finite-lived intangible asset, useful life     7 years  
Amortization       $ 113,660
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member] | In Process Research and Development [Member]        
Finite-Lived Intangible Assets [Line Items]        
Estimated acquisition price     $ 24,200,000  
IPR and D Drug Technology Platforms [Member] | In Process Research and Development [Member]        
Finite-Lived Intangible Assets [Line Items]        
Asset impairment charges     $ 13,400,000  
Non-cash charge $ 13,400,000